Liquidia’s New Study on Inhaled Treprostinil: What Investors Need to Know

Liquidia Technologies ((LQDA)) announced an update on their ongoing clinical study.

Liquidia Technologies is conducting a clinical study titled An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension. The study aims to assess the safety and tolerability of LIQ861, a dry powder inhalation form of treprostinil, in patients with pulmonary hypertension (PH) and interstitial lung disease (ILD). This research is significant as it explores a potentially safer and more effective treatment option for these conditions.

The intervention being tested is LIQ861, a combination product designed as a treprostinil inhalation powder. It is intended to provide a targeted treatment for pulmonary hypertension, potentially improving patient outcomes by delivering medication directly to the lungs.

This observational study follows a cohort model and is prospective in nature, meaning it will observe outcomes over time without manipulating the study environment. The primary focus is on evaluating the safety and tolerability of the treatment over a 52-week period.

The study began on November 6, 2023, with a primary completion date yet to be determined. The most recent update was submitted on May 30, 2025. These dates are crucial as they indicate the study’s progress and timelines for potential results.

The update on this study could influence Liquidia Technologies’ stock performance positively, as successful results may enhance investor confidence and market position. It also places Liquidia in a competitive stance within the pulmonary hypertension treatment market, potentially impacting competitors.

The study is currently recruiting, with further details available on the ClinicalTrials portal.